Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02559492 |
|
Recruitment Status :
Terminated
First Posted : September 24, 2015
Last Update Posted : September 25, 2019
|
Sponsor:
Incyte Corporation
Information provided by (Responsible Party):
Incyte Corporation
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is an open-label, Phase 1b, platform study in subjects with advanced or metastatic solid tumors. The study will be divided into 3 parts (Part 1a, Part 1b, and Part 2). Part 1a will evaluate a JAK inhibitor with JAK1 selectivity (Itacitinib) in combination with an IDO1 inhibitor (epacadostat; INCB024360; Group A) and Itacitinib in combination with a PI3K-delta inhibitor (INCB050465; Group B) to determine the MTD or PAD and the recommended Part 1b doses for each combination. Once the recommended dose has been identified for each treatment group in Part 1a, subjects with advanced solid tumors will be enrolled into expansion cohorts based upon prior treatment history with a PD-1 pathway-targeted agent (Part 1b). In Part 2, additional expansion cohorts will be enrolled to further evaluate lower doses of itacitinib and INCB050465 in subjects with select tumor types.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Solid Tumors | Drug: Itacitinib Drug: Epacadostat Drug: INCB050465 | Phase 1 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 142 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors |
| Study Start Date : | November 2015 |
| Actual Primary Completion Date : | September 10, 2018 |
| Actual Study Completion Date : | August 18, 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Group A: Itacitinib + epacadostat
Group A will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
|
Drug: Itacitinib
Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
Other Name: INCB039110 Drug: Epacadostat Epacadostat tablets will be administered orally, twice daily. |
|
Experimental: Group B: Itacitinib + INCB050465
Group B will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
|
Drug: Itacitinib
Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
Other Name: INCB039110 Drug: INCB050465 INCB050465 tablets will be administered orally once daily. |
Primary Outcome Measures :
- Number of Participants With Dose Limiting Toxicities (DLTs) [ Time Frame: Baseline through 21 days ]Safety and tolerability of the treatment groups.
Secondary Outcome Measures :
- Objective response rate (ORR) [ Time Frame: Every 9 weeks for duration of study participation which is estimated to be 18 months ]Tumor response rates in those subjects with measurable disease.
- Progression Free Survival (PFS) [ Time Frame: Every 9 weeks for duration of study participation which is estimated to be 18 months ]Progression-free survival, defined as the time from enrollment until the earliest date of disease progression.
- Duration of response (DOR) [ Time Frame: Every 9 weeks for duration of study participation which is estimated to be 18 months ]Duration of response determined by radiographic disease assessment.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or female, age 18 years or older.
- Willingness to provide written informed consent for the study.
- Part 1a: Subjects with histologically or cytologically confirmed advanced or metastatic solid tumors that have failed prior standard therapy (including subject refusal or intolerance).
- Part 1b: Subjects with endometrial cancer, gastric cancer, head and neck squamous cell carcinoma, melanoma, microsatellite unstable colorectal cancer, non-small cell lung cancer, pancreatic ductal adenocarcinoma, renal cell carcinoma, triple negative breast cancer, or transitional cell carcinoma of the genitourinary tract that have had disease progression after available therapies for metastatic disease that are known to confer clinical benefit, been intolerant to treatment, or refused standard treatment.
- Part 1b: Must have documented confirmed disease progression on a prior programmed cell death-1 (PD-1) pathway targeted agent or must be PD-1 pathway-targeted treatment naïve.
- Part 2: Subjects with HNSCC, NSCLC, pancreatic ductal adenocarcinoma, salivary gland cancer, and transitional cell carcinoma of the genitourinary tract that have had disease progression after available therapies for advanced or metastatic disease that are known to confer clinical benefit, have been intolerant to treatment, or have refused standard treatment.
- Willingness to undergo a pre-treatment and on-treatment tumor biopsy to obtain the specimen.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion Criteria:
- Laboratory parameters not within the protocol-defined range.
- Receipt of anticancer medications or investigational drugs within a defined interval before the first administration of study drug.
- Received an immune-suppressive based treatment for any reason within 14 days prior to the first dose of study treatment.
- Has not recovered from toxic effect of prior therapy to < Grade 1.
- Active or inactive autoimmune process.
- Has received a live vaccine within 30 days of planned start of study therapy.
- Active infection requiring systemic therapy.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02559492
Locations
| United States, California | |
| Duarte, California, United States | |
| United States, Colorado | |
| Denver, Colorado, United States | |
| United States, Connecticut | |
| New Haven, Connecticut, United States | |
| United States, Florida | |
| Tampa, Florida, United States | |
| United States, Illinois | |
| Chicago, Illinois, United States | |
| United States, Minnesota | |
| Rochester, Minnesota, United States | |
| United States, North Carolina | |
| Huntersville, North Carolina, United States | |
| United States, Tennessee | |
| Nashville, Tennessee, United States | |
| United States, Texas | |
| Dallas, Texas, United States | |
| Houston, Texas, United States | |
| United States, Utah | |
| Salt Lake City, Utah, United States | |
Sponsors and Collaborators
Incyte Corporation
Investigators
| Study Director: | Lance Leopold, MD | Incyte Corporation |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Incyte Corporation |
| ClinicalTrials.gov Identifier: | NCT02559492 |
| Other Study ID Numbers: |
39110-106 |
| First Posted: | September 24, 2015 Key Record Dates |
| Last Update Posted: | September 25, 2019 |
| Last Verified: | September 2019 |
Additional relevant MeSH terms:
|
Neoplasms |